Milestone Pharmaceuticals Inc (MIST) FinancialsMISTMilestone Pharmaceuticals Inc

Evaluating the bottom line, Milestone Pharmaceuticals Inc maintains a gross margin of 94.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9942.44%, while the net margin is -10952.10%. These profitability ratios, combined with a Return on Equity (ROE) of -456.88%, provide a clear picture of how effectively MIST converts its operational activities into shareholder value.

In the context of the broader market, MIST competes directly with industry leaders such as ADCT and CNTB. With a market capitalization of $148.15M, it holds a significant position in the sector. When comparing efficiency, MIST's gross margin of 94.12% stands against ADCT's 88.68% and CNTB's 100.00%. Such benchmarking helps identify whether Milestone Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Milestone Pharmaceuticals reported a revenue of $559,000 in Q2 2026, a significant increase from zero revenue in the previous year, indicating improving market acceptance. However, the company also reported a net loss of $28.6 million for the same quarter, highlighting ongoing financial challenges.